BCL2 and B-cell chronic lymphocytic leukemia: Schwamb et al. reported that treatment with UGCGi sensitized CLL cells in which B cell receptor was engaged by immunoglobulin M stimulation, to a targeted agent, specifically a BCL-2 inhibitor.